Illinois 2023 2023-2024 Regular Session

Illinois House Bill HB3631 Engrossed / Bill

Filed 03/27/2023

                    HB3631 EngrossedLRB103 30054 BMS 56477 b   HB3631 Engrossed  LRB103 30054 BMS 56477 b
  HB3631 Engrossed  LRB103 30054 BMS 56477 b
1  AN ACT concerning regulation.
2  Be it enacted by the People of the State of Illinois,
3  represented in the General Assembly:
4  Section 5. The Illinois Insurance Code is amended by
5  changing Section 513b1 as follows:
6  (215 ILCS 5/513b1)
7  Sec. 513b1. Pharmacy benefit manager contracts.
8  (a) As used in this Section:
9  "340B drug discount program" means the program established
10  under Section 340B of the federal Public Health Service Act,
11  42 U.S.C. 256b.
12  "340B entity" means a covered entity as defined in 42
13  U.S.C. 256b(a)(4) authorized to participate in the 340B drug
14  discount program.
15  "340B pharmacy" means any pharmacy used to dispense 340B
16  drugs for a covered entity, whether entity-owned or external.
17  "Biological product" has the meaning ascribed to that term
18  in Section 19.5 of the Pharmacy Practice Act.
19  "Maximum allowable cost" means the maximum amount that a
20  pharmacy benefit manager will reimburse a pharmacy for the
21  cost of a drug.
22  "Maximum allowable cost list" means a list of drugs for
23  which a maximum allowable cost has been established by a

 

  HB3631 Engrossed  LRB103 30054 BMS 56477 b


HB3631 Engrossed- 2 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 2 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 2 - LRB103 30054 BMS 56477 b
1  pharmacy benefit manager.
2  "Pharmacy benefit manager" means a person, business, or
3  entity, including a wholly or partially owned or controlled
4  subsidiary of a pharmacy benefit manager, that provides claims
5  processing services or other prescription drug or device
6  services, or both, for health benefit plans.
7  "Retail price" means the price an individual without
8  prescription drug coverage would pay at a retail pharmacy, not
9  including a pharmacist dispensing fee.
10  "Third-party payer" means any entity that pays for
11  prescription drugs on behalf of a patient other than a health
12  care provider or sponsor of a plan subject to regulation under
13  Medicare Part D, 42 U.S.C. 1395w-101, et seq.
14  (b) A contract between a health insurer and a pharmacy
15  benefit manager must require that the pharmacy benefit
16  manager:
17  (1) Update maximum allowable cost pricing information
18  at least every 7 calendar days.
19  (2) Maintain a process that will, in a timely manner,
20  eliminate drugs from maximum allowable cost lists or
21  modify drug prices to remain consistent with changes in
22  pricing data used in formulating maximum allowable cost
23  prices and product availability.
24  (3) Provide access to its maximum allowable cost list
25  to each pharmacy or pharmacy services administrative
26  organization subject to the maximum allowable cost list.

 

 

  HB3631 Engrossed - 2 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 3 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 3 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 3 - LRB103 30054 BMS 56477 b
1  Access may include a real-time pharmacy website portal to
2  be able to view the maximum allowable cost list. As used in
3  this Section, "pharmacy services administrative
4  organization" means an entity operating within the State
5  that contracts with independent pharmacies to conduct
6  business on their behalf with third-party payers. A
7  pharmacy services administrative organization may provide
8  administrative services to pharmacies and negotiate and
9  enter into contracts with third-party payers or pharmacy
10  benefit managers on behalf of pharmacies.
11  (4) Provide a process by which a contracted pharmacy
12  can appeal the provider's reimbursement for a drug subject
13  to maximum allowable cost pricing. The appeals process
14  must, at a minimum, include the following:
15  (A) A requirement that a contracted pharmacy has
16  14 calendar days after the applicable fill date to
17  appeal a maximum allowable cost if the reimbursement
18  for the drug is less than the net amount that the
19  network provider paid to the supplier of the drug.
20  (B) A requirement that a pharmacy benefit manager
21  must respond to a challenge within 14 calendar days of
22  the contracted pharmacy making the claim for which the
23  appeal has been submitted.
24  (C) A telephone number and e-mail address or
25  website to network providers, at which the provider
26  can contact the pharmacy benefit manager to process

 

 

  HB3631 Engrossed - 3 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 4 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 4 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 4 - LRB103 30054 BMS 56477 b
1  and submit an appeal.
2  (D) A requirement that, if an appeal is denied,
3  the pharmacy benefit manager must provide the reason
4  for the denial and the name and the national drug code
5  number from national or regional wholesalers.
6  (E) A requirement that, if an appeal is sustained,
7  the pharmacy benefit manager must make an adjustment
8  in the drug price effective the date the challenge is
9  resolved and make the adjustment applicable to all
10  similarly situated network pharmacy providers, as
11  determined by the managed care organization or
12  pharmacy benefit manager.
13  (5) Allow a plan sponsor contracting with a pharmacy
14  benefit manager an annual right to audit compliance with
15  the terms of the contract by the pharmacy benefit manager,
16  including, but not limited to, full disclosure of any and
17  all rebate amounts secured, whether product specific or
18  generalized rebates, that were provided to the pharmacy
19  benefit manager by a pharmaceutical manufacturer.
20  (6) Allow a plan sponsor contracting with a pharmacy
21  benefit manager to request that the pharmacy benefit
22  manager disclose the actual amounts paid by the pharmacy
23  benefit manager to the pharmacy.
24  (7) Provide notice to the party contracting with the
25  pharmacy benefit manager of any consideration that the
26  pharmacy benefit manager receives from the manufacturer

 

 

  HB3631 Engrossed - 4 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 5 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 5 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 5 - LRB103 30054 BMS 56477 b
1  for dispense as written prescriptions once a generic or
2  biologically similar product becomes available.
3  (c) In order to place a particular prescription drug on a
4  maximum allowable cost list, the pharmacy benefit manager
5  must, at a minimum, ensure that:
6  (1) if the drug is a generically equivalent drug, it
7  is listed as therapeutically equivalent and
8  pharmaceutically equivalent "A" or "B" rated in the United
9  States Food and Drug Administration's most recent version
10  of the "Orange Book" or have an NR or NA rating by
11  Medi-Span, Gold Standard, or a similar rating by a
12  nationally recognized reference;
13  (2) the drug is available for purchase by each
14  pharmacy in the State from national or regional
15  wholesalers operating in Illinois; and
16  (3) the drug is not obsolete.
17  (d) A pharmacy benefit manager is prohibited from limiting
18  a pharmacist's ability to disclose whether the cost-sharing
19  obligation exceeds the retail price for a covered prescription
20  drug, and the availability of a more affordable alternative
21  drug, if one is available in accordance with Section 42 of the
22  Pharmacy Practice Act.
23  (e) A health insurer or pharmacy benefit manager shall not
24  require an insured to make a payment for a prescription drug at
25  the point of sale in an amount that exceeds the lesser of:
26  (1) the applicable cost-sharing amount; or

 

 

  HB3631 Engrossed - 5 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 6 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 6 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 6 - LRB103 30054 BMS 56477 b
1  (2) the retail price of the drug in the absence of
2  prescription drug coverage.
3  (f) Unless required by law, a contract between a pharmacy
4  benefit manager or third-party payer and a 340B entity or 340B
5  pharmacy shall not contain any provision that:
6  (1) distinguishes between drugs purchased through the
7  340B drug discount program and other drugs when
8  determining reimbursement or reimbursement methodologies,
9  or contains otherwise less favorable payment terms or
10  reimbursement methodologies for 340B entities or 340B
11  pharmacies when compared to similarly situated non-340B
12  entities;
13  (2) imposes any fee, chargeback, or rate adjustment
14  that is not similarly imposed on similarly situated
15  pharmacies that are not 340B entities or 340B pharmacies;
16  (3) imposes any fee, chargeback, or rate adjustment
17  that exceeds the fee, chargeback, or rate adjustment that
18  is not similarly imposed on similarly situated pharmacies
19  that are not 340B entities or 340B pharmacies;
20  (4) prevents or interferes with an individual's choice
21  to receive a covered prescription drug from a 340B entity
22  or 340B pharmacy through any legally permissible means,
23  except that nothing in this paragraph shall prohibit the
24  establishment of differing copayments or other
25  cost-sharing amounts within the benefit plan for covered
26  persons who acquire covered prescription drugs from a

 

 

  HB3631 Engrossed - 6 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 7 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 7 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 7 - LRB103 30054 BMS 56477 b
1  nonpreferred or nonparticipating provider;
2  (5) excludes a 340B entity or 340B pharmacy from a
3  pharmacy network on any basis that includes consideration
4  of whether the 340B entity or 340B pharmacy participates
5  in the 340B drug discount program;
6  (6) prevents a 340B entity or 340B pharmacy from using
7  a drug purchased under the 340B drug discount program; or
8  (7) any other provision that discriminates against a
9  340B entity or 340B pharmacy by treating the 340B entity
10  or 340B pharmacy differently than non-340B entities or
11  non-340B pharmacies for any reason relating to the
12  entity's participation in the 340B drug discount program.
13  As used in this subsection, "pharmacy benefit manager" and
14  "third-party payer" do not include pharmacy benefit managers
15  and third-party payers acting on behalf of a Medicaid program.
16  (g) A violation of this Section by a pharmacy benefit
17  manager constitutes an unfair or deceptive act or practice in
18  the business of insurance under Section 424.
19  (h) A provision that violates subsection (f) in a contract
20  between a pharmacy benefit manager or a third-party payer and
21  a 340B entity that is entered into, amended, or renewed after
22  July 1, 2022 shall be void and unenforceable.
23  (i)(1) A pharmacy benefit manager may not retaliate
24  against a pharmacist or pharmacy for disclosing information in
25  a court, in an administrative hearing, before a legislative
26  commission or committee, or in any other proceeding, if the

 

 

  HB3631 Engrossed - 7 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 8 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 8 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 8 - LRB103 30054 BMS 56477 b
1  pharmacist or pharmacy has reasonable cause to believe that
2  the disclosed information is evidence of a violation of a
3  State or federal law, rule, or regulation.
4  (2) A pharmacy benefit manager may not retaliate against a
5  pharmacist or pharmacy for disclosing information to a
6  government or law enforcement agency, if the pharmacist or
7  pharmacy has reasonable cause to believe that the disclosed
8  information is evidence of a violation of a State or federal
9  law, rule, or regulation.
10  (3) A pharmacist or pharmacy shall make commercially
11  reasonable efforts to limit the disclosure of confidential and
12  proprietary information.
13  (4) Retaliatory actions against a pharmacy or pharmacist
14  include cancellation of, restriction of, or refusal to renew
15  or offer a contract to a pharmacy solely because the pharmacy
16  or pharmacist has:
17  (A) made disclosures of information that the
18  pharmacist or pharmacy has reasonable cause to believe is
19  evidence of a violation of a State or federal law, rule, or
20  regulation;
21  (B) filed complaints with the plan or pharmacy benefit
22  manager; or
23  (C) filed complaints against the plan or pharmacy
24  benefit manager with the Department.
25  (j) (i) This Section applies to contracts entered into or
26  renewed on or after July 1, 2023 2022.

 

 

  HB3631 Engrossed - 8 - LRB103 30054 BMS 56477 b


HB3631 Engrossed- 9 -LRB103 30054 BMS 56477 b   HB3631 Engrossed - 9 - LRB103 30054 BMS 56477 b
  HB3631 Engrossed - 9 - LRB103 30054 BMS 56477 b
1  (k) (j) This Section applies to any group or individual
2  policy of accident and health insurance or managed care plan
3  that provides coverage for prescription drugs and that is
4  amended, delivered, issued, or renewed on or after July 1,
5  2020.
6  (Source: P.A. 101-452, eff. 1-1-20; 102-778, eff. 7-1-22;
7  revised 8-19-22.)

 

 

  HB3631 Engrossed - 9 - LRB103 30054 BMS 56477 b